Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Toxicology and Applied Pharmacology|July 1, 1995
Reaction between metabolically activated acetaminophen and phosphorothioate oligonucleotidesB L Copple, W M Gmeiner, P L Iversen
Toxicology Letters|December 1, 1995
Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and manP L Iversen, B L Copple, H K Tewary
Methods in Molecular Medicine|March 2, 2011
Continuous infusion of antisense phosphorothioate therapeuticsP L Iversen, B L Copple, H K Tewary, et al.
Current Opinion in Molecular Therapeutics|August 11, 2001
Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivationP L Iversen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignanciesM R Bishop, P L Iversen, E Bayever, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 14, 2001
Hepatic and extrahepatic factors critical for liver injury during lipopolysaccharide exposureF Moulin, B L Copple, P E Ganey, et al.
Current Opinion in Molecular Therapeutics|August 11, 2001
Redirection of drug metabolism using antisense technologyV Arora, P L Iversen
General Pharmacology|November 1, 1994
Metallothionein in carcinogenesis and cancer chemotherapyM Ebadi, P L Iversen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2000
Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivoV Arora, P L Iversen
Antisense & Nucleic Acid Drug Development|September 13, 2000
Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomersC Ghosh, P L Iversen
Pageof 8